# Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

> **NCT04909853** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 35 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** PF-07321332/ritonavir

## Key facts

- **NCT ID:** NCT04909853
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-15
- **Primary completion:** 2021-10-07
- **Final completion:** 2021-10-07
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04909853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04909853, "Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04909853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*